Preclinical studies highlighted that in the case of lung cancer, once/week administration of the formulation in a xenograft model at a dose of 5 mg/kg inhibited the tumor growth with no evident side effects, while the in vitro studies performed on MDA-MB-231 triple negative breast cancer cell line evidenced a near total inhibition of mammosphere formation compared to paclitaxel by selectively binding to the CD44 marker [112,113,116]. This evidence concerns the gene CD44 and triple-negative breast carcinoma.